Scarica l'app Stockscreener
81.12
1.99%
-1.65
Dopo l'orario di chiusura:
81.12
Tarsus Pharmaceuticals Inc Borsa (TARS) Ultime notizie
Tarsus Pharmaceuticals Finalizes Acquisition of Alkeus Pharmaceuticals with $270M Cash and Stock Deal - Kalkine Media
Tarsus Pharmaceuticals COO Neervannan Seshadri Offloads 4,564 Shares at $85 Each (NASDAQ: TARS) - Kalkine Media
Tarsus Pharmaceuticals CEO Bobak Azamian Executes Open-Market Sale of 10,000 Shares at $90.27-$91.27 (NASDAQ: TARS) - Kalkine Media
Tarsus Pharmaceuticals CMO Executes Stock Sales Under Dual 10b5-1 Trading Plans - Kalkine Media
Tarsus (NASDAQ: TARS) CEO sells 10,000 shares under 10b5-1 plan - Stock Titan
Jefferies raises Tarsus Pharmaceuticals price target on guidance By Investing.com - Investing.com Nigeria
Tarsus Pharmaceuticals gains analyst boost afte... - Pluang
TARS Maintains by Jefferies -- Price Target Raised to $105 - GuruFocus
Tarsus Finalizes Alkeus Acquisition, Expanding Eyecare Pipeline - VisionMonday.com
TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme - Stocktwits
Tarsus Pharmaceuticals stock hits all-time high at 85.29 USD By Investing.com - Investing.com South Africa
Tarsus Pharmaceuticals CEO Bobak R. Azamian Offloads 10,000 Shares at $80.06 Each (NASDAQ: TARS) - Kalkine Media
Officer at Tarsus (NASDAQ: TARS) lines up six-figure stock sale - Stock Titan
After recent sales, Tarsus (NASDAQ: TARS) officer's spouse plans another stock trade - Stock Titan
About $943K in stock set for sale at Tarsus (TARS) - Stock Titan
Planned Tarsus (TARS) officer sale covers 4,564 shares - Stock Titan
Tarsus Pharmaceuticals Shares Rise After Closing Alkeus Pharmaceuticals Acquisition - marketscreener.com
Tarsus Pharmaceuticals stock hits all-time high at 85.29 USD - Investing.com
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care - The Manila Times
A potentially blinding eye disease has no FDA-approved therapy. Tarsus bought a company developing one. - Stock Titan
Tarsus Pharmaceuticals (TARS) CEO sells 10,000 shares in plan trade - Stock Titan
Shareholder plans new stock sale at Tarsus (NASDAQ: TARS) - stocktitan.net
Former Tarsus (NASDAQ: TARS) officer plans another stock sale - Stock Titan
Tarsus (NASDAQ: TARS) exec plans $431K sale after recent $340K stock cash-out - Stock Titan
Tarsus (NASDAQ: TARS) officer lines up another stock sale - Stock Titan
Tarsus to Participate in Upcoming Investor Conferences - The Manila Times
Ex-officer lines up third multimillion sale in Tarsus (NASDAQ: TARS) stock - Stock Titan
Planned $340K insider stock sale at Tarsus (NASDAQ: TARS) from vested pay - stocktitan.net
Form 144 | Tarsus Pharmaceuticals(TARS.US) Insider Proposes to Sell 5.75 Million in Common Stocks - Moomoo
After $3.8M sale, Tarsus (TARS) ex-officer plans more selling - Stock Titan
Tarsus (TARS) Technicals: Finishes 1.69% Up at $72.70 in the Latest Session; Next Test: Support at $69.06 and Resistance at $76.34 Frame the Range in Latest TradingVWAP Bounce - vinanet.vn
Tarsus (NASDAQ: TARS) ex-officer plans sale of 53K shares - Stock Titan
Form 144 | Tarsus Pharmaceuticals(TARS.US) Insider Proposes to Sell 3.82 Million in Common Stocks - Moomoo
Midday Stock Roundup: Eledon Falls 3.5% - Orange County Business Journal
TimesSquare Capital Management LLC Takes $23.25 Million Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Why Tarsus Pharmaceuticals (TARS) Is Up 6.8% After Raising XDEMVY 2026 Sales GuidanceAnd What's Next - Sahm
Tarsus Pharmaceuticals (TARS) Shares Just Moved, What Is Behind The Attention? - Sahm
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Q2 2026 Tarsus Pharmaceuticals, Inc. Earnings Call Transcript - GuruFocus
Tarsus Pharmaceuticals (TARS) Stock Looks Reasonable On Sales While Earnings Stay Weak - Yahoo Finance
William Blair Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating - Moomoo
Janus Henderson Group Ltd. (TARS) discloses 6.5% beneficial stake in Tarsus - Stock Titan
Wasatch Advisors LP Buys New Holdings in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
How (TARS) Movements Inform Risk Allocation Models - Stock Traders Daily
Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Tarsus Pharmaceuticals (TARS) Holds Above $65 Support After Modest Pullback to $68.68Gap Up Stocks - vinanet.vn
TARS Maintained by Oppenheimer -- Price Target Raised to $100 - GuruFocus
Oppenheimer Adjusts PT on Tarsus Pharmaceuticals to $100 From $97, Keeps Outperform Rating - marketscreener.com
Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $100 - Moomoo
Tarsus Pharmaceuticals (TARS) Surges 4.6% to $67.76, Pressing Against ResistanceChandelier Stop - vinanet.vn
Tarsus Pharmaceuticals Signs Agreement to Acquire Alkeus Pharmaceuticals - Global Legal Chronicle
The Manufacturers Life Insurance Company Cuts Stock Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Tarsus Pharmaceuticals, Inc. $TARS Shares Acquired by Bank of America Corp DE - MarketBeat
Why Tarsus Pharmaceuticals (TARS) Is Up 9.7% After Raising XDEMVY 2026 Sales Guidance And Acquiring Alkeus - Sahm
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):